Fig. 4: The combination of BCL2 and MCL1 inhibitors induced early hallmarks of apoptosis in HMCLs. | Cell Death & Disease

Fig. 4: The combination of BCL2 and MCL1 inhibitors induced early hallmarks of apoptosis in HMCLs.

From: Dual targeting of BCL2 and MCL1 rescues myeloma cells resistant to BCL2 and MCL1 inhibitors associated with the formation of BAX/BAK hetero-complexes

Fig. 4

a Immunoblot of caspase 9 and 3 activation in KMM1 and LP1 HMCLs after 3 and 5 h of S63845 and/or venetoclax treatment. b Caspase activation was monitored by live-cell imaging using IncuCyte S3 during 15 h exposure to S63845 (50 nM) and/or venetoclax (100 nM) and in the presence of a Caspase 3–7 dye. Results represent the mean ± SD of two independent experiments. c Transfection of KMM1 and LP1 HMCLs with scramble, BIM or NOXA siRNA for 48 h followed by 24 h of S63845 (50 nM) and/or venetoclax (100 nM). Cell death was assessed by Annexin V staining. Silencing efficacy was validated by immunoblotting. Results represent the mean ± SD of five independent experiments. Mann–Whitney test was used for statistical analysis (*p < 0.05).

Back to article page